Clinical Trials
19 trialsNCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT03860987 2026-05-22
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02772588 2026-04-13
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03298087 2025-08-01
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
VA Office of Research and Development
Phase 2 Completed
NCT03414034 2024-11-07
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Cardiff Oncology
Phase 2 Completed
NCT04207255 2024-09-25
Addition of Opaganib to Androgen Antagonists in Patients With mCRPC
Medical University of South Carolina
Phase 2 Completed
NCT01972217 2023-11-14
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
AstraZeneca
Phase 2 Completed
NCT02789878 2022-09-15
Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer
Instituto do Cancer do Estado de São Paulo
Phase 2 Completed
NCT02867020 2021-07-07
Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels
Latin American Cooperative Oncology Group
Phase 2 Completed
NCT03418324 2020-12-30
Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT02036060 2020-11-16
ABIDO
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT02429193 2020-01-13
BARRIER-P
University Health Network, Toronto
Phase 2 Completed
NCT01553188 2019-03-05
AMG 386 and Abiraterone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01677897 2019-03-05
MetAb-Pro
Kantonsspital Graubünden
Phase 2 Completed
NCT01756638 2017-10-23
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed
NCT01795703 2015-11-04
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel
Janssen Research & Development, LLC
Phase 2 Completed
NCT01424930 2014-07-25
A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen-Ortho Inc., Canada
Phase 2 Completed
NCT00924469 2013-04-17
A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer
Janssen Research & Development, LLC
Phase 2 Completed